Physiotherapeutic bath

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to physiotherapy, balneotherapy. Taking baths is realised. Bath includes gas-saturated water, and beer. Saturation with gas is performed by addition of fresh non-filtered beer in ratio 1:10 and supply of air, heated to 25°C from bottom to top. 1/2 part of water, heated to 40°C is poured into bathtub. After that, beer is added and then water, heated to 40°C, in amount of remaining 1/2 part. Bathtub is made from oak with holes.

EFFECT: method increases efficiency of bath realisation due to complex impact on organism with thermal and chemical factors and aeromassage.

 

The invention relates to physiotherapy, in particular, to complex baths, providing a healing effect due to the combination of various factors hydropathic procedures.

Known gas bath consisting of water, saturated with gas (see Ponomarenko G.N. Manual physical therapy, St. Petersburg: Baltic, 2005).

However, physiotherapeutic effect gas baths is limited, since the effect due to the structure of the saturating water gas and its solubility.

Famous baths complex, which in addition to dissolved gases are present and dissolved substances, for example, aromatic (see Antonov "Hydrotherapy - easy and affordable", Moscow: OLMA-Press invest, 2005, prototype)

However, physiotherapeutic effect of these baths is low.

The present invention solves the problem of increasing the effectiveness of physiotherapy through complex effects on the human body.

The technical result is the simultaneous impact on human thermal and chemical factors - heated aqueous solution of beer, and mechanical - Aero the entire surface of the body over time, intended for relaxation of the body.

The problem is solved in that physiotherapy bath consisting of water, in which the saturation of the gas and dissolved substances Ave is found by adding fresh unfiltered beer in the ratio of 1:10, serving upwards of air heated to 25°C, and filling the bath in the following order: first the bath tubs pour 1/2 part water, heated to 40°C, add the beer and add water, heated to 40°C, the number of remaining 1/2 part, the font baths are made of oak with holes that match the criteria of the invention of "novelty."

Comparison of the claimed invention, not only the prototype, but also with other sources of information shows that the physical effect of the invention is enhanced by aeration, promotes massage at the same time the whole body of a person and due to the density of the beer effect increases, for example, in comparison with gas baths, high temperature environment provides the pores open, the saturation of the body with b vitamins, which does not presuppose no known therapeutic baths, and trace elements. The hops contained in beer, affects the human nervous system and causes an additional effect of relaxation. Tannins released from oak baptismal font, reinforce this effect and have an aromatherapy effect. Natural beer foam, as section of a liquid and gaseous environments, is a porous structure and increases the mobility of air bubbles, settling and evaporates from the surface t is La man enhancing the effect of Aero, at the time of making one physiotherapy bath (30 minutes), i.e. the patient is not necessary to move from bath to receive a massage, and then, for example, to aromatherapy that meet the criterion of "inventive step".

The invention is implemented as follows.

In font of oak, fitted at the bottom of the holes, pour water, heated to 40°C in the amount of12from the total mass of water. In the water, add fresh unfiltered beer in the ratio of 1:10 and pour the remaining 1/2 of the water, also heated to 40°C. Through the holes from the bottom up to deliver air heated to 25°C. Bubbling air bubbles pass through the thickness of the formed solution, provide Aero and create on the surface a rich lather. In a prepared bath is placed person to receive treatments for 30 minutes.

Example.

Group of persons, 38 men and women took beer baths. Until the aperture baths dermatologist and physician conducted a survey, examination, measurement of blood pressure and heart rate. In 13 individuals revealed a small increase in blood pressure.

After taking 5 treatments was again conducted a medical examination, which showed the following.

In 89% normalized frequency with technich cuts.

The skin became more velvety, smooth and elastic at 79%, and, after the adoption of procedures for hyperhidrosis, decreased perspiration by 50%, and the dryness of the skin's natural hydration increased by 30%.

47% improved hair structure, increased their natural Shine, decreased hair loss by 24%.

However, persons who prior to admission procedures revealed increased blood pressure, systolic blood pressure decreased by 20-25%, diastolic blood pressure decreased by 15%.

Improve the overall tone of the body after administration procedures noted in 79%, and the maximum increase is observed after 12-14 hours.

62% of men reported an improvement in sexual potency, which causes the increase of the efficacy of physical baths.

Physiotherapy bath consisting of water saturated with gas and dissolved substances, characterized in that the protective gas and the dissolved substances carried out by adding fresh unfiltered beer in the ratio of 1:10, flow bottom to top air, heated to 25°C, and first in the font baths pour 1/2 part water, heated to 40°C, add the beer and add water, heated to 40°C, the number of remaining 1/2 part, and the font baths are made of oak with holes.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes methods of treating an angiogenesis regulated disorder, involving the administration of an effective amount of the human protein tyrosine phosphatase beta (HPTPβ) binding antibody to an individual. Binding the antibody to HPTPβ improves Tie-2 signal transmission and thereby regulates (increases or decrease) angiogenesis depending on the disease. The used antibody is produced by the hybridoma ATCC №PTA-7580. The antibody provides a basis to prepare a pharmaceutical composition for treating the angiogenesis regulated disease which contains both the antibody, and a pharmaceutically acceptable carrier.

EFFECT: methods according to the invention are used to treat the disorders accompanied by decreased or increased angiogenesis, particularly the diseases such as musculoskeletal or myocardial ischemia, stroke, coronary artery and peripheral vascular disease, sickle-cell anaemia, Paget disease, Lyme disease and others.

7 cl, 12 dwg, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for correction of sleep-wake schedule desynchronosis. Thee above agent for correction of sleep-wake schedule desynchronosis representing a dry water extract of an elevated part of agrimony (Agrimonia pilosa Ledeb.) prepared by water extraction of the elevated part of agrimony collected when came into flower, cooling of the extract, filtration followed by cake extraction in water, cooling, filtration; further the cake is filled with water, filtered; the prepared extracts are combined; the solvent is removed, and the residue is dried under certain circumstances.

EFFECT: agent is effective to correct sleep-wake schedule desynchronosis.

4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy, and may be used for treating chronic diseases. That is ensured by a course of acupuncture massage and hirudotherapy procedures. The therapeutic course additionally contains procedures of administering a preparation produced by mixing patient's venous blood and water for injections, as well as procedures of capillary blood-letting. The acupuncture massage is paravertebral along the spine with each session of the course started from the 7th cervical vertebrae downwards, including the lumbosacral region to localise painful points and to prepare the patient's body to the procedure of administering the preparation produced by mixing patient's venous blood and water for injections; the above procedure extends paravertebrally along the spine; each session of the course covers 2 points from each side in relation to the spine starting from the 7th cervical vertebrae to the 2nd thoracic vertebra in the first session of the course and downwards for each session of the course, and then the produced preparation is administered into 2 points from each side along the spine, including the lumbosacral region. Before the procedure of administering the preparation, vacuum cups are placed on the painful points localised during the procedure of acupuncture massage, while the hirudotherapy therapy is carried out at the end of the whole therapeutic course covering the lumbosacral region.

EFFECT: method enables the short-term recovery ensured by the stable immune recovery with the systemic body effect.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy, and may be used for treating chronic fatigue syndrome. That is ensured by an integrated therapy providing the simultaneous exposure on three links of the pathological chain: excessive regulatory T cell accumulation, depletion of the hypothalamus-pituitary-adrenal axis, visceral obesity. The drug preparations used to manage the excessive regulatory T cell accumulation are intravenous alkylating preparations as follows: endoxane 800 mg/day or alkerane 10 mg/day administered every second months for three-five times; the drug preparations used to recover the hypothalamus-pituitary-adrenal axis activity is the macrolide antibiotic klacid in a single dose of 250 mg/day or prednisolone 5 mg/day administered every second day within min. 6-month therapeutic course; the drug preparation used to treat visceral obesity is the ACE inhibitor Prestarium in a single dose of 2.5 mg/day with the length of the therapeutic course being not less than one year.

EFFECT: method enables a more stable effect ensured by selective elimination of the regulatory T cells and cell growth modification, immunomodulatory and anti-inflammatory activity, protective effect on the cardiovascular system.

3 ex

Azole compounds // 2493154

FIELD: chemistry.

SUBSTANCE: invention relates to compounds which are pyridin-3-yl 4-(3-phenyl-1H-1,2,4-triazol-5-yl)piperidine-1-carboxylate, 6-methylpyridin-3-yl 4-[3-(4-fluoromethyl)-1H-1,2,4-triazol-5-yl]piperidine-1-carboxylate, 6-methylpyridin-3-yl 4-[5-(4-fluorophenyl)-1,3-oxazol-2-yl]piperidine-1-carboxylate, 2,6-dimethylpyridin-3-yl 4-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]piperidine-1-carboxylate, 2-methylpyridin-3-yl 4-[3-(2-fluorophenyl)-1H-1,2,4-triazol-5-yl]piperidine-1-carboxylate, 6-methylpyridin-3-yl 4-(3-phenyl-1H-pyrazol-1-yl)piperidine-1-carboxylate, 2-methylpyridin-3-yl 4-[5-(3-fluorophenyl)-1,3-oxazol-2-yl]piperidine-1-carboxylate and 6-methylpyridin-3-yl 4-[4-(4-fluorophenyl)-1,3-oxazol-2-yl]piperidine-1-carboxylate or to a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on said compounds, having inhibiting effect on fatty acid amide hydrolase (FAAH).

EFFECT: obtaining novel compounds and a pharmaceutical composition based on said compounds, which can be used in medicine for treating neuropathic pain.

13 cl, 38 tbl, 159 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, pharmacology, to methods and PTEN phosphatase inhibitor compositions for ovarian follicle and oocyte development in vitro. Using the PTEN phosphatase inhibitors, such as complexes of oxovanadate and peroxovanadate: bisperoxo (bipyridine) oxovanadate, bisperoxo (1,10-phenanthroline) oxovanadate, bisperoxo (picolinato) oxovanadate, bisperoxo (5-hydroxypyridine-2-carboxyl) oxovanadate, di- (picolinat) oxovanadate, di-(3-hydroxypicolinat) oxovanadate, bisperoxo (phenylbiguanide) oxovanadate, di-(phenylbiguanide) oxovanadate and bisperoxo (isoquinoline carboxylic acid) oxovanadate, provide the development and activation in vitro of oocytes and follicles, such as primordial, intermediate and primary ovarian follicles.

EFFECT: invention provides the development and activation in vitro of oocytes and follicles, such as primordial, intermediate and primary ovarian follicles.

14 cl, 3 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically to genetically engineered compositions for therapeutic agent delivery into a patient's tumour, and may be used in medicine. The composition contains a therapeutically effective amount of a pharmaceutical composition of a functional Fc fragment of an antibody bound to one or more SPARC-binding polypeptides (SBP), and a pharmaceutically acceptable carrier. The composition is used in a method for delivery of a therapeutic agent containing the functional Fc fragment of the antibody.

EFFECT: invention provides the effective delivery of the therapeutic agent to the SPARC-expressing tumour in a mammal.

12 cl, 16 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented prolonged release pharmaceutical oral dosage form for preventing or treating an upper gastrointestinal disorder (dyspepsia, epigastric burning, erosive esophagitis, gastrooesophageal reflux disease, peptic ulcer, esophagitis, Barrett's esophagus and esophageal adenocarcinoma), containing a therapeutically effective amount of at least one bile acid sequestrant specified in colesevelam and colesevelam hydrochloride, and a carrier composition providing gastric retention containing one or more hydrogels, wherein the dosage form expands upon contact with gastric juice, respective methods of treating or preventing the upper gastrointestinal disorder and protecting the multilayer squamous epithelium against an attack of any hazardous substances by administering the composition, and a kit for the same application comprising the composition, a label or a package insert with instructions for use. The composition may contains a proton pump inhibitor, and one or more agents specified in antacids, histamine H2-receptor antagonists, γ-aminobutyric acid-b (GABA-B) agonists, and protease inhibitors.

EFFECT: invention aims at retaining the active agent in the stomach for relieving and improving prolonged delivery thereof.

16 cl, 2 ex

FIELD: medicine.

SUBSTANCE: acute venous thrombosis is simulated in a laboratory animal - rat. A mesenchymal stem cell suspension of the concentration of min. 1×106 cell/ml in the amount of 30-50 mcl is introduced into a thrombosed vein lumen. The mesenchymal stem cell suspension is introduced at 0.5 cm below the created thrombus towards the thrombus. The establishment of thrombosed vein flow is thereafter visualised by the common techniques.

EFFECT: substantially activated thrombus revascularisation and establishment of the adequate tissue flow.

3 cl, 4 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to organic chemistry and specifically to novel morpholinopurine derivatives of general formula

,

or a pharmaceutically acceptable salt thereof, where R1 and R2, each independent of each other, denote a C1-C6 alkyl group or a hydrogen atom, R3a and R3b, each independent of each other, denote a C1-C6 alkyl group which can contain three substitutes selected from a group A, or a hydrogen atom, R4 denotes a C1-C6 alkyl group or a hydrogen atom, Ra denotes a group of formula -Y-R , where Y denotes a single bond or a C1-C6 alkylene group, R5 is a C1-C6 alkyl group which can contain one, two or three substitutes selected from group A, a tetrahydrofuranyl group, a pyrrolidinyl group which contains one substitute selected from a group D, and Rb and Rc, each independent of each other, denote a C1-C6 alkyl group which contains one substitute selected from a group E, or a hydrogen atom, or Rb and Rc, together with a nitrogen atom to which they are bonded, for a 5-7-member alicyclic nitrogen-containing heterocyclic group, which is pierazine, morpholine, pyrrolidine, piperidine, homopiperazine, which can contain one, two or three substitutes selected from group E; group A: halogen atom, hydroxy group, C3-C8 cycloalkyl group and oxy group; group D: C1-C6 alkylsulphonyl group; and group E: hydroxy group, formyl group, C1-C6 alkyl group, which can contain one substitute selected from said group A, diC1-C6 alkylamino group, C1-C6 alkylsulphonylamino group, C1-C6alkylsulphonyl C1-C6 alkylamino group, C1-C6 alkylsulphonylamino C1-C6alkyl group, C1-C6alkylcarbonyl group, which can contain one substitute selected from said group A, C1-C6 alkylsulphonyl group, C1-C6 alkylamino C1-C6 alkylcarbonyl group, diC1-C6 alkylamino C1-C6alkylcarbonyl group, which can contain one substitute selected from said group A, diC1-C6 alkylaminocarbonyl group, phenylsulphonyl group and hateroaryl C1-C6 alkylcarbonyl group, where the heteroaryl is imidazolyl. The invention also relates to a pharmaceutical composition, an inhibitor of phosphatidylinositol-3-kinase (PI3K), an inhibitor of mammalian target of rapamycin (mTOR) based on the compound of formula (1a), a method of treating cancer and use of the compound of formula (1a).

EFFECT: obtaining novel morpholinopurine derivatives, having useful biological properties.

42 cl, 19 tbl, 138 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and deals with treatment of acute optic neuritis. Method includes introduction of traumeel sublingually in dose 1 pill three times per day, lymphomyosot in dose 10 drops in 50-100 ml of water three times per day for 3 weeks. Also made are 10 injection cpurses of the following medications: traumeel in dose 2.2 ml every second day, cerebrum compositum in dose 2.2 ml two times per week with 3 day interval, coenzyme compositum in dose 2.2 ml two times per week with 3 day interval, hepar compositum in dose 2.2 ml two days per week with 3 day interval. Method includes carrying out hirudotherapy by application of 2-3 leeches on the region of temple and behind ears two times per week for two weeks.

EFFECT: method ensures recovery of vision acuity, elimination of absolute and relative scotomas, recovery of colour perception, normal picture of eye fundus, as well as elimination of all signs of inflammation, elimination of pain during movement of eye balls, improvement of health state.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurology, and may be used for treating lumbar and cervical intervertebral hernias. That is ensured by conducting a dispersion therapy by injections of drug preparations exhibiting the enzymatic properties. That is followed by a combined exposure to a constant magnetic field and low-power pulse visible and near-infrared light emission. The dispersion therapy involves arresting an acute pain with diprospan 2 ml. Further, a mixture of Traumeel C 10 ml and Chymotrypsin 10 mg or Lydase 64 IU with Chymotrypsin and Lydase alternated is administered 7-10 times twice a week. Herewith, the epidural puncture is slow for 30-60 seconds at the level of a cicatrical process and a hernia-involved disc segment to provide the infiltration of the scar epidural subcutaneous fat at the level of epiduritis. What is used therefor is a fine needle with the skin pre-anaesthetised. The anaesthetic solution is administered intermittently in a dose of 2-3 ml every 40-60 sec.

EFFECT: method enables making the process of hernia dispersion as fast as possible and reducing a probability of a recurrence accompanying the non-operative treatment of the intervertebral hernia.

1 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely to an agent for treating alcoholic toxicosis. The declared agent contains an enzymatic hydrolysis product of mixed cereals and cereal grains in the relation of 1:9 to 1:25 and cereal flour, wherein the amount of cereal flour makes 1.0-20.0 wt %. As a cereal, the declared agent contains pearlbarley or oatmeal or buckwheat, and as a cereal grains - wheat or barley or corn.

EFFECT: invention provides pharmacological stimulation of the endogenous ethanol synthesis and normalisation of the carbohydrate metabolism.

7 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for correction of sleep-wake schedule desynchronosis. Thee above agent for correction of sleep-wake schedule desynchronosis representing a dry water extract of an elevated part of agrimony (Agrimonia pilosa Ledeb.) prepared by water extraction of the elevated part of agrimony collected when came into flower, cooling of the extract, filtration followed by cake extraction in water, cooling, filtration; further the cake is filled with water, filtered; the prepared extracts are combined; the solvent is removed, and the residue is dried under certain circumstances.

EFFECT: agent is effective to correct sleep-wake schedule desynchronosis.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to neurology, and concerns using ginkgo biloba leaf extract for treating and preventing dementia syndrome. That is ensured by using the extract containing flavones 22 wt % to 27 wt % , bilobalides 2.6 wt % to 3.2 wt % and ginkgolides A, B and C (total) 2.8 wt % to 3.4 wt % and ginkgolic acid max. 5 mcg/g. The extract of the above formulation is administered orally once a day in a dose of 240 mg.

EFFECT: dose schedule provides the effective treatment and prevention of mild and moderate dementia.

20 cl, 3 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, particularly to an agent for preventing and treating opisthorchiasis. The agent for preventing and treating opisthorchiasis on the basis of herbal extract containing an aqueous and/or lipid complex of pine and fir straw as herbal extract and an active ingredient.

EFFECT: agent is effective for preventing and treating opisthorchiasis.

6 cl, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to ophthalmology. The ophthalmic preparations are used in ophthalmic diseases as a lacrimal substitute, and they contain a combination of hyaluronic acid and a polysaccharide known as TSP (a Tamarindus indica seed polysaccharide). The ophthalmic preparations suggested to be used in treating a dry eye syndrome contain in a combination of 0.05 to 2 wt % of the tamarind seed polysaccharide and 0.05 to 1 wt % of hyaluronic acid in the aqueous solution.

EFFECT: when administered in a combination of hyaluronic acid and TSP, the invention provides a synergistic effect in stimulating the normal conjunctival mucosa recovery if affected by the dry eye syndrome, thereby inducing a noticeable improvement of the number and morphology of the conjunctival microvilli.

16 cl, 9 tbl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention relates to cosmetic industry, in particular to preparation for women's intimate hygiene. Application of coniferous natural water extract as active component of preparation for women's intimate hygiene. Preparation for women's intimate hygiene, which contains coniferous natural water extract and soapy base, taken in specified ratio. Preparation for women's intimate hygiene for prevention and treatment of gynecological diseases, which contains coniferous natural water extract and soapy base, taken in specified ratio.

EFFECT: preparations are effective for women's intimate hygiene, have increased antibacterial activity, do not cause irritation on mucosa and skin, as well as have increased duration of influence of active components.

9 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of cosmetology, namely, to nonwoven and elastomeric substrates, as well as to multi-layer products, in which applied is one or more nonwoven and elastomeric substrates, which contain compositions in form of lotion or cream, containing oil substance, for ensuring benefit for health and/or hygiene of skin, where composition contains at least one silicone-containing cosmetic carrier and over 5% (by weight of composition) water, where composition has permittivity less than 40.0 and where elastomeric substrate preserves at least 40% of non-processed substrate tension at 30% elongation.

EFFECT: invention ensures improved compatibility of compositions with substrates; in particular, compositions can be applied on substrates without impairing elastomeric properties and general integrity of substrate.

20 cl, 18 ex, 20 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of cosmetology and represents two-component foam-forming hair dye, which includes first preparation, which contains alkaline preparation, second preparation, which contains hydrogen peroxide, and non-aerosol container with foaming agent for discharge of mixture of first and second preparations in form of foam, where first preparation contains: component (A), representing water-soluble cationic polymer, selected from group, which consists of cationic celluloses, cationic starches, polymers or copolymers of quaternary salts of diallylammonium and quaternised polyvinylpyrrolidones; component (B), which represents ion of alkaline metal in concentration from 0.20 to 2.00 mole/kg; component (C1), representing oxidation dye, which contains phenol hydroxyl group, in concentration 0.05 mole/kg or more; and optionally component (C2), representing anion surface-active substance, with total concentration of components (C1) and (C2) in first preparation constituting from 0.16 to 0.50 mole/kg; and viscosity of mixture at temperature 25°C constitutes from 1 to 300 mPa·s.

EFFECT: invention ensures improvement of stability in storage of first preparation, improvement of mixture discharge characteristics and characteristics of hair dyeing.

7 cl, 15 ex, 6 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and aims at treating irritable bowel syndrome with diarrhoea. What is used is a low-mineralised sodium hydrocarbonate Abalakhskaya mineral water (AMW) with an faintly alkaline reaction of aqueous medium. The complex therapeutic course makes 21 days including drinking therapy - 18 days, a single drinking dose of AMW of temperature 38-40°C is gradually increased from 50-80 ml to 180-200 ml; the procedures of duodenal drainage are performed with the use of AMW of temperature 37-38°C in the amount of 200 ml of a single dose; for the procedures of intestinal irrigations, AMW is pre-heated to 40-42°C, while a single dose makes 500 ml gradually increased to 800 ml; the procedures of intestinal irrigations are alternated with baths.

EFFECT: method provides higher clinical effectiveness in irritable bowel syndrome, normalised intestinal motility.

2 ex

Up!